The safety and efficacy of tocilizumab in patients with neuromyelitis optica: Multicenter Study - Tocilizumab in patients with neuromyelitis optica: Multicenter Study

Department of Immunology, National Institute of Neuroscience, NCNP0 个研究点目标入组 15 人开始时间: 2012年5月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Patients with severe infection such as tuberculosis, pneumocystis carinii pneumonia, nontuberculous mycobacterial infection, hepatitis B, hepatitis C, or chronic active EB virus infection. 2) Patients with a history of tuberculosis infection or patients with pleural thickness or old tuberculin in chest X-ray. 3) Patients with a history of hypersensitivity to this drug. 4) Patients with a history of intestinal diverticulum. 5) Patients with interstitial pneumonitis. 6) Patients with leukopenia (white blood cell number < 4000/mm3), lymphopenia (lymphocyte number < 1000/mm3) or seropositivity for beta-D-glucan in peripheral blood. 7) Pregnant women or patients with possible pregnancy. 8) Patients who can not provide consent to participate in this study by themselves. 9) Patients whose EDSS are more than 7.

发起方

Department of Immunology, National Institute of Neuroscience, NCNP